A behind-the-scenes look at the 2025 Breakthrough East agenda

BREAKTHROUGH EAST | NYC + ONLINE

A behind-the-scenes look at this year's agenda

Dear readers,

We are less than a month away from STAT Breakthrough Summit East in New York — and what a time to be planning an event about the state of pharmaceutical research and development.

These are, of course, uncertain times for all fields of science. What is certain is that we will have a full day of discussions that will give you a line of sight into both how policy will affect research and some of the hottest areas in research itself. Some examples:

Pfizer's chief strategy officer, Andrew Baum, will join STAT for his first interview about his work at the drug giant.

STAT's Adam Feuerstein will introduce us to two companies earning hard-won successes against the liver disease called MASH, associated with obesity.

STAT's Allison DeAngelis will interview venture capitalist and serial biotech builder Ken Song (his last company sold for $4.1 billion) about everything from getting funding to licensing drugs from China.

That's not all! We'll have a debate on telehealth, direct-to-consumer ads, and GLP-1s, a look at how diversity efforts in clinical trials are being reshaped, and Bill Nye. We're working on sessions on CRISPR and vaccines. You can take a look at the whole agenda here.

I promise a day that will teach you a lot about where new treatments are coming from, and give you a widened perspective that you'll be able to take back to your daily work. I hope to see you there!